StockNews.AI
EXAS
StockNews.AI
110 days

Exact Sciences Announces First-Quarter 2025 Results

1. EXAS reported $707 million revenue in Q1 2025, up from $638 million in Q1 2024. 2. CEO claims 2025 will be transformative with new tests launched.

Earnings
+9.31%Current Return
VS
+1.49%S&P 500
$47.1605/01 04:15 PM EDTEvent Start
$51.5505/02 10:48 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

EXAS's revenue growth indicates strong market demand, reminiscent of past successful quarters that drove share price increases.

How important is it?

The revenue increase and new product offerings are critical indicators of EXAS's growth trajectory and investor interest.

Why Long Term?

Sustained revenue growth and innovative product launches suggest potential for continued market dominance over several quarters.

Related Companies

GRAILVRTXDGX
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $707 million for the first quarter ended March 31, 2025, compared to $638 million for the same period of 2024. “Our strong first quarter results pave the way for 2025 to mark our most transformative year yet,” said Kevin Conroy, chairman and CEO. “The Exact Sciences team just launched two innovative tests: Cologua.

Related News